Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love Sells 5,021 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 5,021 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $2.95, for a total transaction of $14,811.95. Following the transaction, the chief executive officer now directly owns 351,554 shares of the company’s stock, valued at approximately $1,037,084.30. This represents a 1.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Annexon Stock Performance

Shares of NASDAQ:ANNX opened at $2.70 on Wednesday. Annexon, Inc. has a 1 year low of $2.70 and a 1 year high of $8.40. The stock has a market capitalization of $287.79 million, a P/E ratio of -2.57 and a beta of 1.07. The stock has a 50-day simple moving average of $4.41 and a 200-day simple moving average of $5.63.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $15.80.

Hedge Funds Weigh In On Annexon

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Parkman Healthcare Partners LLC boosted its holdings in Annexon by 0.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock worth $1,945,000 after acquiring an additional 1,768 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Annexon by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after acquiring an additional 2,450 shares during the period. GSA Capital Partners LLP boosted its holdings in Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after acquiring an additional 3,355 shares during the period. E Fund Management Co. Ltd. boosted its holdings in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Annexon by 6.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after acquiring an additional 4,092 shares during the period.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.